ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Risk factors for immune checkpoint inhibitor-related interstitial lung disease: a retrospective cohort study.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) for cancer treatment show a high incidence of immune-related adverse events (irAEs), among which severe interstitial lung disease (ILD) can be fatal, requiring prompt identification and management. This study aimed to identify pre-treatment risk factors associated with ICI-induced ILD. Medical records of patients who received ICIs were retrospectively reviewed. Age, sex, body weight, primary tumor type, ICI agent, PD-L1 status, disease stage, line of treatment, and laboratory parameters measured before treatment initiation were collected. Smoking history and prior diagnoses of chronic obstructive pulmonary disease and ILD were recorded. Patients who developed ILD were compared with those who did not. Elevated pre-treatment C-reactive protein (CRP) levels (odds ratio [OR] = 1.877; 95% confidence interval [CI] = 1.238-2.845; p = 0.003) and increased monocyte counts (OR = 23.509; 95% CI = 1.375-4.020 × 10
Indexed as
Identifiers
42262534What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.